Ghent-based Nuclivision, a Belgian medtech startup, has secured €5M in funding. The investment comes from LUMO Labs, Heran Partners, and the imec.istart future fund.
The funds will support the commercial launch of Nuclivision’s AI software platform, Nuclarity. The platform is designed to improve medical imaging processes using PET scans.
PET, or positron emission tomography, is an imaging technique that allows visualisation of physiological processes, including cellular energy consumption and related abnormalities. The method relies on radiotracers, which involve costs and radiation exposure. These factors currently limit the technique’s accessibility.
Geoffrey D’hondt from Heran Partners, says, “Nuclivision is uniquely positioned in the field of AI-driven image enhancement for PET scans with the Nuclarity platform. By reducing the amount of time and the amount of costly and harmful radiotracers required for accurate medical imaging, Nuclarity not only reduces the time pressure on nuclear medicine departments but also the cost and harmful environmental and health impact of PET scans.”
Enhancing patient care in nuclear medicine
Founded in 2022 by Maarten Larmuseau, Tomas Brants and Simon DeKeyser, Nuclivision develops software that enables PET scans to be completed with less radiation and in shorter timeframes, while maintaining diagnostic accuracy.
The software reduces reliance on radiotracers, lowering both financial and health-related barriers linked to PET technology.
PET imaging, used to visualise physiological processes such as cellular energy use and related irregularities, remains limited in availability due to its cost and radiation exposure. Nuclivision addresses these issues through software that improves scan efficiency and lowers environmental impact by optimising the use of radiopharmaceuticals.
Focused on areas such as oncology, neurology, and theranostics, Nuclivision aims to support earlier and safer detection of conditions, including cancer and Alzheimer’s.
Nuclivision’s CEO, Maarten Larmuseau, says, “Medical imaging is at an inflection point. With the rapid growth within radiopharma and theranostics, the use of AI and smart software is becoming necessary to handle the increased demand for PET and SPECT scans for conditions such as cancer and Alzheimer’s.”
Nuclivision, guided by professor-clinicians and industry experts, is preparing to expand across Europe once approval is complete and later this year to the US to improve access to diagnoses and treatments. The company is in the final regulatory approval phase for its software platform.
“The completion of the regulatory approval process marks the beginning of a new growth phase for Nuclivision that is crucial for the actual deployment and impact of their technology,” adds Sven Bakkes, Founding Partner at LUMO Labs.
He continues, “We look forward to supporting the founders and the growing team of Nuclivision in this, of course, with indispensable growth capital but also with expertise and frameworks in the field of business operations and impact and with opening up our network.”
Brief about LUMO Labs
Founded in 2016 by Andy Lürling and Sven Bakkes, LUMO Labs invests in impact-driven software and smart hardware startups through its multi-stage LUMO Fund II, which includes a two-year venture builder programme.
It supports startups aligned with UN Sustainable Development Goals, focusing on AI, blockchain, IoT, robotics, drones, and VR/AR. LUMO Labs promotes data ownership, transparency, and technological traceability.
LUMO Rise Fund, a €100M VC fund managed by LUMO Labs, supports early to growth-stage startups through investment and a dedicated startup coaching programme. The fund targets founders using technology to address social and environmental challenges.
The fund primarily invests in the Benelux region and Germany, with additional interest in the Nordics, Baltics, and the Iberian Peninsula.
